{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:13:27Z","timestamp":1783556007853,"version":"3.55.0"},"reference-count":30,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2002,9,19]],"date-time":"2002-09-19T00:00:00Z","timestamp":1032393600000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ANZ Journal of Surgery"],"published-print":{"date-parts":[[2002,9]]},"abstract":"<jats:p>\n            <jats:bold>Background:<\/jats:bold> \u2003Carcinoid tumours are rare neoplasms that secrete hormones and biogenic amines, most commonly serotonin. Octreotide and long acting lanreotide are found to be useful in the management of carcinoid syndrome by its interaction with somatostatin receptor, found on the carcinoid tumour. The aim of this study is to look at the efficacy of octreotide and long acting lanreotide in the treatment of symptomatic non\u2010resectable carcinoid tumours.<\/jats:p><jats:p>\n            <jats:bold>Method:<\/jats:bold> \u2003The effects of octreotide and long\u2010acting lanreotide were studied in 10 patients with symptomatic non\u2010resectable carcinoid tumours.<\/jats:p><jats:p>\n            <jats:bold>Results:<\/jats:bold> \u2003Symptom improvement occurred in nine of 10 patients. Three patients responded only to octreotide, three patients responded to both octreotide and long\u2010acting lanreotide and three patients only responded to long\u2010acting lanreotide. Slight reductions in 24\u2010h urine 5\u2010hydroxyindoleacetic acid levels occurred in three of six patients but no patients were found to have objective tumour regression on computed tomography scan.<\/jats:p><jats:p>\n            <jats:bold>Conclusions:<\/jats:bold> \u2003Octreotide and long\u2010acting lanreotide are useful palliative treatments for the control of symptoms in patients with non\u2010resectable carcinoid tumours but there is no evidence of tumour stasis.<\/jats:p>","DOI":"10.1046\/j.1445-2197.2002.02507.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T02:50:21Z","timestamp":1047351021000},"page":"635-638","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Use of octreotide and lanreotide in the treatment of symptomatic non\u2010resectable carcinoid tumours"],"prefix":"10.1111","volume":"72","author":[{"given":"Muhammad","family":"Rohaizak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Richard","family":"Farndon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,9,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01966242"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-3-209"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(57)90354-6"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(85)90009-5"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02939369"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90583-8"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(68)91528-6"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19861115)58:10<2290::AID-CNCR2820581022>3.0.CO;2-4"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.2.279"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.465_q.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000007693"},{"key":"e_1_2_6_13_2","first-page":"104","article-title":"Carcinoid tumours: An analysis of 2837 cases","volume":"45","author":"Godwin JD","year":"1980","journal-title":"Cancer"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2"},{"key":"e_1_2_6_15_2","first-page":"322","article-title":"Carcinoid tumours: Frequency in a defined population study during a 12\u2010year period","volume":"84","author":"Berge T","year":"1976","journal-title":"Acta Pathol. Microbiol. Scand. (A)"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-4-199402150-00008"},{"key":"e_1_2_6_18_2","first-page":"33","article-title":"The carcinoid syndrome: A treatable malignant disease","volume":"2","author":"Kvols LK","year":"1986","journal-title":"Oncology"},{"key":"e_1_2_6_19_2","first-page":"217","article-title":"Somatostatin analog phase I trials in neuroendocrine neoplasms","volume":"32","author":"Anthony L","year":"1993","journal-title":"ActaOncol."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1310577"},{"key":"e_1_2_6_21_2","first-page":"5969","article-title":"Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoid and islet cells carcinomas","volume":"50","author":"Reubi JC","year":"1990","journal-title":"CancerRes."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117090"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1111"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841869709001323"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000201401"},{"key":"e_1_2_6_26_2","first-page":"38","volume-title":"British National Formulary.","author":"British Medical Association and the Royal Pharmaceutical Societyof Great Britain.","year":"1999"},{"key":"e_1_2_6_27_2","first-page":"225","article-title":"Long term management of the carcinoid syndrome. Treatment with octreotidealone and in combination with alpha\u2010interferon","volume":"32","author":"Janson ET","year":"1993","journal-title":"ActaOncol."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-80035-1_12"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841869109092411"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2001.110426"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199704000-00003"}],"container-title":["ANZ Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1445-2197.2002.02507.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1445-2197.2002.02507.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1445-2197.2002.02507.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T13:09:49Z","timestamp":1698757789000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1445-2197.2002.02507.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["10.1046\/j.1445-2197.2002.02507.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1445-2197.2002.02507.x","archive":["Portico"],"relation":{},"ISSN":["1445-1433","1445-2197"],"issn-type":[{"value":"1445-1433","type":"print"},{"value":"1445-2197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,9]]},"assertion":[{"value":"2002-09-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}